BeiGene
BeiGene

BeiGene

DR69Ahrefs DR: 69/100. Above median. Measured by Ahrefs. Median 44.Agent56Agent Readiness: 56/100. Top 25%. Measured by StartupHub.ai. Median 41.Speed66Site Speed: 66/100. Above median. Measured by Google PageSpeed. Median 62.

A global oncology company developing and commercializing innovative cancer treatments.

2010ActiveCambridge, United States

About

BeOne Medicines is a global oncology company dedicated to discovering, developing, and commercializing transformative cancer medicines. They focus on advancing a broad pipeline through rigorous science, including pioneering protein degradation with CDACs and antibody drug conjugates, to serve patients worldwide. BeOne Medicines aims to build the world's leading oncology company, driven by scientific excellence and speed to reach more patients.

Key facts

At-a-glance profile data

Website
beonemedicines.com
Headquarters
Cambridge, Massachusetts, U.S.
Founded
2010
Total funding
$358M (Secondary Offering)
Business model
B2B

Funding rounds

Funding rounds raised by BeiGene
DateRoundAmountLead investors
23 Nov 2016Secondary Offering$200M-
1 Feb 2016IPO$158M-

Tech stack

Detected on beonemedicines.com and in its job posts, last scanned 22 Oct 2026.

Frontend
jQuery, Tailwind CSS, Bootstrap
Backend
Python, .NET, Java
Database
Elasticsearch, PostgreSQL
SEO
Yoast SEO
CMS / Builders
WordPress
CDN
Cloudflare
Hosting
Google Cloud, Azure, AWS
Email provider
Microsoft 365
Hiring platform
Workday
Mobile
Swift
Add first review

Frequently asked

How much funding has BeiGene raised?

BeiGene has raised a total of $358M in funding. The most recent round on record is Secondary Offering.